Visualization analysis of research hotspots and development trends of hyperkalemia in hemodialysis patients_West China Medical Journal

Authors：

ZHU Lin ¹ , ZHENG Haotian ¹ , WAN Zhenghong ¹ , HE Li ¹ ,  ZHOU Li ²

1. Hemodialysis Department of Nephrology, West China Hospital, Sichuan University / West China School of Nursing, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Hemodialysis Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

ZHOU Li, Email: 446125447@qq.com

Keywords：

Hemodialysis; hyperkalemia; research hotspots; visualization analysis

DOI：

10.7507/1002-0179.202406163

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the research hotspots and trends in the field of hyperkalemia in hemodialysis patients at home and abroad, and to provide reference for the research and prevention and control of hyperkalemia in hemodialysis patients. Methods China National Knowledge Infrastructure (CNKI) and Web of Science databases were searched by computer for literature about the hyperkalemia in hemodialysis patients published between January 1995 and January 2023. The included literature was analyzed using visualization analysis tools for visualization, including high-frequency keywords, keyword co-occurrence map, keyword emergence intensity and keyword time series prediction. Results A total of 10 275 articles were included. Among them, there were 10 036 articles from web of science and 239 articles from CNKI. The number of articles in this research field showed a trend of steady increase year by year. The United States was in a leading position in the research and development in this field, followed by China. At the same time, the research in this field presents the characteristics of multidisciplinary integration. The development trends of research hotspots in the next 5 years were risk and health education research. Conclusions The number of research articles related to hyperkalemia in hemodialysis patients is gradually increasing. Multidisciplinary approach and integration is a research hotspot and frontier in the development of hyperkalemia in hemodialysis patients both domestically and internationally.

Citation： ZHU Lin, ZHENG Haotian, WAN Zhenghong, HE Li, ZHOU Li. Visualization analysis of research hotspots and development trends of hyperkalemia in hemodialysis patients. West China Medical Journal, 2024, 39(8): 1259-1264. doi: 10.7507/1002-0179.202406163 Copy

1.	葉倩呈, 王三營, 劉倩影, 等. 維持性血液透析患者自體動靜脈內瘺失功風險預測模型的研究進展. 中國護理管理, 2022, 22(7): 1102-1105.
2.	羅培藝, 馬良, 茍慎菊. 合并危險因素的高鉀血癥診治進展. 中國全科醫學, 2022, 25(36): 4587-4594.
3.	黃耀禹, 毛慧娟, 邢昌贏. 維持性血液透析患者的高鉀血癥管理進展. 中國血液凈化, 2021, 20(12): 793-796.
4.	Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Kidney Int, 2020, 97(6): 1117-1129.
5.	孫靜, 杜玄一. 慢性腎臟病高鉀血癥發病機制及治療進展. 實用臨床醫藥雜志, 2021, 25(5): 125-128.
6.	中華醫學會腎臟病分會專家組. 中國慢性腎臟病患者血鉀管理實踐專家共識. 中華腎臟病雜志, 2020, 36(10): 781-792.
7.	鄭法雷, 章友康, 陳香美, 等. 慢性腎臟病——公共衛生領域的新挑戰——寫在 2009“世界腎臟日”之前. 北京醫學, 2009, 31(3): 129-130.
8.	周國民, 李建民. 從“溫陽法”論治慢性腎功能衰竭高鉀血癥. 中華中醫藥雜志, 2020, 35(6): 2939-2942.
9.	王沖, 李月紅. 維持性血液透析患者血鉀波動的危害及干預策略. 腎臟病與透析腎移植雜志, 2020, 29(4): 386-389, 368.
10.	高玉梅, 吳桃峰, 林麗華, 等. 風險評估工具在血液透析患者高鉀血癥分級管理中的應用. 中國血液凈化, 2022, 21(9): 692-696.
11.	Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int, 2020, 97(1): 42-61.
12.	Ding X, Yang Z. Knowledge mapping of platform research: a visual analysis using VOSviewer and CiteSpace. Electron Commer Res, 2022, 22(3): 787-809.
13.	郭富蒸, 張麗穎, 于皓南, 等. 早復極綜合征的再認識. 中國老年學雜志, 2018, 38(4): 1007-1010.
14.	蔣建平, 譚佳英, 雷炎, 等. 血液透析搶救高鉀血癥所致惡性心律失常臨床分析. 臨床心血管病雜志, 2010, 26(3): 229.
15.	Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation, 2022, 145(19): 1460-1470.
16.	Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: managing potassium and renal function. Cleve Clin J Med, 2019, 86(9): 601-607.
17.	Wen Y, Xia Y, Gong Y. Effects and safety of sacubitril/valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients. Am J Transl Res, 2022, 14(5): 3439-3447.
18.	Kosiborod M, Cherney D, Desai AS, et al. Design of Phase Ⅳ, double-blind, placebo-controlled, randomized-withdrawal trial evaluating sodium zirconium cyclosilicate for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction (REALIZE-K Trial). Circ, 2021, 144(Suppl 1): A8895.
19.	Fishbane S, Charytan DM, Chertow GM, et al. Consensus-based recommendations for the management of hyperkalemia in the hemodialysis setting. J Ren Nutr, 2022, 32(4): e1-e14.
20.	Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, et al. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA heart failure long-term registry. Revista espa?ola de cardiología (English ed. ), 2020, 73(4): 313-323.
21.	Sumida K, Lau WL, Kovesdy CP, et al. Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Curr Opin Nephrol Hypertens, 2021, 30(1): 75-84.
22.	Kaze AD, Zhuo M, Kim SC, et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol, 2022, 21(1): 47.
23.	劉衛華, 林紫寧, 洪富源. 血液透析并發心力衰竭的防治新進展. 中國實用內科雜志, 2021, 41(11): 917-921.
24.	Yang A, Singh B, Lavin PT, et al. Placebo effect in clinical studies in hyperkalemia: a double-blind, randomized, placebo-controlled phase 3 study of sodium zirconium cyclosilicate (ZS-9). Am J Kidney Dis, 2015, 65(4): A91.
25.	董建華, 王緒臻, 范文靜, 等. 環硅酸鋯鈉治療維持性血液透析患者慢性高鉀血癥的療效. 腎臟病與透析腎移植雜志, 2022, 31(1): 15-20.
26.	張潔婷, 梁玉婷, 魏爽, 等. 血液透析患者透析相關知識知曉情況及其影響因素分析. 中國血液凈化, 2019, 18(11): 791-794.
27.	王婷婷, 馬迎春. 維持性血液透析患者運動康復的實施及影響因素. 中國血液凈化, 2019, 18(3): 204-206.
28.	胡瑞, 邱文龍, 趙喜紅, 等. 從腎移植術后感染新冠肺炎談免疫宿主低下人群的管理. 中華危重病急救醫學, 2022, 34(5): 492-496.
29.	Bhatt GC, Sethi SK, Mehta I, et al. Literature review of the efficacy of high-volume hemofiltration in critically ill pediatric patients. Blood Purif, 2022, 51(8): 649-659.
30.	Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med, 2014, 370(15): 1383-1392.
31.	Choi JY, Cho SG, Jang KS, et al. Voriconazole-induced Severe Hyperkalemia Precipitated by Multiple Drug Interactions. Electrolyte Blood Press, 2020, 18(1): 10-15.
32.	Dos Santos RG, Malinovski J, Scatone N, et al. MO595 frequency of intake of dietary fiber sources not associated with hyperkalemia in hemodialys patients in a multicenter study. Nephrol Dial Transpl, 2021, 36(Suppl 1): gfab089-008.
33.	姜美. 研究尿毒癥患者輸血發生高鉀血癥原因及護理. 中國現代藥物應用, 2017, 11(16): 166-167.
34.	李萍, 錢巧慧, 崔麗, 等. 醫聯體內知識共享的范疇研究. 中國全科醫學, 2018, 21(13): 1539-1545.
35.	Rossignol P, Pitt B. Heart failure and chronic kidney disease patients. J Am Coll Cardiol, 2021, 78(4): 344-347.
36.	劉宏, 劉必成. 慢性腎臟病合并高鉀血癥: 老問題、新對策. 中華醫學雜志, 2021, 101(42): 3447-3450.
37.	Gaudry S, Quenot JP, Hertig A, et al. Timing of renal replacement therapy for severe acute kidney injury in critically ill patients. Am J Respir Crit Care Med, 2019, 199(9): 1066-1075.
38.	Chen H, Cheng Q, Wang J, et al. Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta‐analysis including 13, 146 patients. J Clin Pharm Ther, 2021, 46(4): 999-1009.
39.	Brueske B, Sidhu MS, Schulman‐Marcus J, et al. Hyperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients. J Am Heart Assoc, 2019, 8(7): e011814.
40.	Thongprayoon C, Cheungpasitporn W, Radhakrishnan Y, et al. Association of serum potassium derangements with mortality among patients requiring continuous renal replacement therapy. Ther Apher Dial, 2022, 26(6): 1098-1105.
41.	陳洪, 周春華. 2007 年北京市新入血液透析患者病因組成分析. 中國血液凈化, 2009, 8(10): 567-570.
42.	Lisi F, Grande D, Parisi G, et al. Hyperkalemia is the main cause of mineralocorticoid receptor antagonists withdrawal and is associate with a worse prognosis in patients with chronic heart failure. Eur Heart J Suppl, 2019, 21(E): E230-E231.
43.	Lowe KM, Cruz JB, Jones KM. Complications in patients with chronic kidney disease. Crit Care Nurs Clin North Am, 2022, 34(4): 395-407.
44.	Stevens JS, Hastie JM, Spellman J, et al. Optimizing perioperative renal replacement therapy for patients undergoing cardiac surgical procedures requiring cardiopulmonary bypass. Blood Purif, 2022: 1-7.
45.	Conley R, Rich RL, Montero J. Safety of a nurse-driven standardized potassium replacement protocol in critically ill patients with renal insufficiency. Crit Care Nurse, 2021, 41(2): e10-e16.

1. 葉倩呈, 王三營, 劉倩影, 等. 維持性血液透析患者自體動靜脈內瘺失功風險預測模型的研究進展. 中國護理管理, 2022, 22(7): 1102-1105.
2. 羅培藝, 馬良, 茍慎菊. 合并危險因素的高鉀血癥診治進展. 中國全科醫學, 2022, 25(36): 4587-4594.
3. 黃耀禹, 毛慧娟, 邢昌贏. 維持性血液透析患者的高鉀血癥管理進展. 中國血液凈化, 2021, 20(12): 793-796.
4. Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Kidney Int, 2020, 97(6): 1117-1129.
5. 孫靜, 杜玄一. 慢性腎臟病高鉀血癥發病機制及治療進展. 實用臨床醫藥雜志, 2021, 25(5): 125-128.
6. 中華醫學會腎臟病分會專家組. 中國慢性腎臟病患者血鉀管理實踐專家共識. 中華腎臟病雜志, 2020, 36(10): 781-792.
7. 鄭法雷, 章友康, 陳香美, 等. 慢性腎臟病——公共衛生領域的新挑戰——寫在 2009“世界腎臟日”之前. 北京醫學, 2009, 31(3): 129-130.
8. 周國民, 李建民. 從“溫陽法”論治慢性腎功能衰竭高鉀血癥. 中華中醫藥雜志, 2020, 35(6): 2939-2942.
9. 王沖, 李月紅. 維持性血液透析患者血鉀波動的危害及干預策略. 腎臟病與透析腎移植雜志, 2020, 29(4): 386-389, 368.
10. 高玉梅, 吳桃峰, 林麗華, 等. 風險評估工具在血液透析患者高鉀血癥分級管理中的應用. 中國血液凈化, 2022, 21(9): 692-696.
11. Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int, 2020, 97(1): 42-61.
12. Ding X, Yang Z. Knowledge mapping of platform research: a visual analysis using VOSviewer and CiteSpace. Electron Commer Res, 2022, 22(3): 787-809.
13. 郭富蒸, 張麗穎, 于皓南, 等. 早復極綜合征的再認識. 中國老年學雜志, 2018, 38(4): 1007-1010.
14. 蔣建平, 譚佳英, 雷炎, 等. 血液透析搶救高鉀血癥所致惡性心律失常臨床分析. 臨床心血管病雜志, 2010, 26(3): 229.
15. Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation, 2022, 145(19): 1460-1470.
16. Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: managing potassium and renal function. Cleve Clin J Med, 2019, 86(9): 601-607.
17. Wen Y, Xia Y, Gong Y. Effects and safety of sacubitril/valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients. Am J Transl Res, 2022, 14(5): 3439-3447.
18. Kosiborod M, Cherney D, Desai AS, et al. Design of Phase Ⅳ, double-blind, placebo-controlled, randomized-withdrawal trial evaluating sodium zirconium cyclosilicate for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction (REALIZE-K Trial). Circ, 2021, 144(Suppl 1): A8895.
19. Fishbane S, Charytan DM, Chertow GM, et al. Consensus-based recommendations for the management of hyperkalemia in the hemodialysis setting. J Ren Nutr, 2022, 32(4): e1-e14.
20. Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, et al. Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA heart failure long-term registry. Revista espa?ola de cardiología (English ed. ), 2020, 73(4): 313-323.
21. Sumida K, Lau WL, Kovesdy CP, et al. Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Curr Opin Nephrol Hypertens, 2021, 30(1): 75-84.
22. Kaze AD, Zhuo M, Kim SC, et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol, 2022, 21(1): 47.
23. 劉衛華, 林紫寧, 洪富源. 血液透析并發心力衰竭的防治新進展. 中國實用內科雜志, 2021, 41(11): 917-921.
24. Yang A, Singh B, Lavin PT, et al. Placebo effect in clinical studies in hyperkalemia: a double-blind, randomized, placebo-controlled phase 3 study of sodium zirconium cyclosilicate (ZS-9). Am J Kidney Dis, 2015, 65(4): A91.
25. 董建華, 王緒臻, 范文靜, 等. 環硅酸鋯鈉治療維持性血液透析患者慢性高鉀血癥的療效. 腎臟病與透析腎移植雜志, 2022, 31(1): 15-20.
26. 張潔婷, 梁玉婷, 魏爽, 等. 血液透析患者透析相關知識知曉情況及其影響因素分析. 中國血液凈化, 2019, 18(11): 791-794.
27. 王婷婷, 馬迎春. 維持性血液透析患者運動康復的實施及影響因素. 中國血液凈化, 2019, 18(3): 204-206.
28. 胡瑞, 邱文龍, 趙喜紅, 等. 從腎移植術后感染新冠肺炎談免疫宿主低下人群的管理. 中華危重病急救醫學, 2022, 34(5): 492-496.
29. Bhatt GC, Sethi SK, Mehta I, et al. Literature review of the efficacy of high-volume hemofiltration in critically ill pediatric patients. Blood Purif, 2022, 51(8): 649-659.
30. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med, 2014, 370(15): 1383-1392.
31. Choi JY, Cho SG, Jang KS, et al. Voriconazole-induced Severe Hyperkalemia Precipitated by Multiple Drug Interactions. Electrolyte Blood Press, 2020, 18(1): 10-15.
32. Dos Santos RG, Malinovski J, Scatone N, et al. MO595 frequency of intake of dietary fiber sources not associated with hyperkalemia in hemodialys patients in a multicenter study. Nephrol Dial Transpl, 2021, 36(Suppl 1): gfab089-008.
33. 姜美. 研究尿毒癥患者輸血發生高鉀血癥原因及護理. 中國現代藥物應用, 2017, 11(16): 166-167.
34. 李萍, 錢巧慧, 崔麗, 等. 醫聯體內知識共享的范疇研究. 中國全科醫學, 2018, 21(13): 1539-1545.
35. Rossignol P, Pitt B. Heart failure and chronic kidney disease patients. J Am Coll Cardiol, 2021, 78(4): 344-347.
36. 劉宏, 劉必成. 慢性腎臟病合并高鉀血癥: 老問題、新對策. 中華醫學雜志, 2021, 101(42): 3447-3450.
37. Gaudry S, Quenot JP, Hertig A, et al. Timing of renal replacement therapy for severe acute kidney injury in critically ill patients. Am J Respir Crit Care Med, 2019, 199(9): 1066-1075.
38. Chen H, Cheng Q, Wang J, et al. Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta‐analysis including 13, 146 patients. J Clin Pharm Ther, 2021, 46(4): 999-1009.
39. Brueske B, Sidhu MS, Schulman‐Marcus J, et al. Hyperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients. J Am Heart Assoc, 2019, 8(7): e011814.
40. Thongprayoon C, Cheungpasitporn W, Radhakrishnan Y, et al. Association of serum potassium derangements with mortality among patients requiring continuous renal replacement therapy. Ther Apher Dial, 2022, 26(6): 1098-1105.
41. 陳洪, 周春華. 2007 年北京市新入血液透析患者病因組成分析. 中國血液凈化, 2009, 8(10): 567-570.
42. Lisi F, Grande D, Parisi G, et al. Hyperkalemia is the main cause of mineralocorticoid receptor antagonists withdrawal and is associate with a worse prognosis in patients with chronic heart failure. Eur Heart J Suppl, 2019, 21(E): E230-E231.
43. Lowe KM, Cruz JB, Jones KM. Complications in patients with chronic kidney disease. Crit Care Nurs Clin North Am, 2022, 34(4): 395-407.
44. Stevens JS, Hastie JM, Spellman J, et al. Optimizing perioperative renal replacement therapy for patients undergoing cardiac surgical procedures requiring cardiopulmonary bypass. Blood Purif, 2022: 1-7.
45. Conley R, Rich RL, Montero J. Safety of a nurse-driven standardized potassium replacement protocol in critically ill patients with renal insufficiency. Crit Care Nurse, 2021, 41(2): e10-e16.

West China Medical Journal

Visualization analysis of research hotspots and development trends of hyperkalemia in hemodialysis patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content